石墨烯脑机接口首进美国，让帕金森告别“一刀切”刺激

Core Viewpoint - InBrain Neuroelectronics has partnered with Mayo Clinic to accelerate the clinical validation and commercialization of its graphene-based brain-computer interface platform (BCI-Tx), marking a significant step towards entering the U.S. market [1][2][17] Group 1: Collaboration Content and Significance - The partnership involves a non-exclusive technical collaboration to evaluate the BCI-Tx platform in an ethically approved environment, aiming to enhance clinical benefits through the integration of graphene and AI technologies [2][5] - InBrain's CEO emphasized the importance of Mayo Clinic's expertise in expediting the validation process within real-world workflows [2][5] Group 2: Product Structure, Function, and Technical Features - The BCI-Tx platform features a cortical interface made of ultra-thin flexible graphene electrode arrays (approximately 10 μm thick), which allows for high-resolution recording and stimulation [3][11] - The platform can support up to 1,024 contact points, enabling a closed-loop approach to record, decode, and modulate neural activity for therapeutic purposes [11][12] Group 3: Industry Comparison and Clinical Application Pathways - InBrain's BCI-Tx platform differs from traditional metal electrodes, which may cause tissue inflammation or scarring due to their rigidity [14] - The platform is positioned as a precision therapeutic BCI, utilizing AI algorithms for dynamic neural modulation, contrasting with the fixed parameter stimulation of deep brain stimulation (DBS) [16][17] - The initial focus is on Parkinson's disease, with potential applications in stroke rehabilitation, epilepsy, and neuropsychiatric disorders [16][17] Group 4: Progress in Various Regions - InBrain's headquarters and R&D are located in Barcelona, Spain, with significant funding support from the Spanish PERTE Chip program [16] - The company has established a U.S. subsidiary in Boston to serve as a clinical trial hub and plans to expand its treatment applications beyond Parkinson's disease [16] - As of 2025, InBrain has raised approximately $124 million, with backing from various industry and research capital resources [16]